Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Inclusion Criteria: * 50 years of age or older * A diagnosis of choroidal neovascularization secondary to age-related macular degeneration (AMD) with choroidal neovascularization (CNV) comprising at least 50% of the total lesion area in the study eye * Central retinal thickness ≥ 300 μm and presence of subretinal fluid or cystoid edema by Optical Coherence Tomography (OCT) * Best Corrected Visual Acuity (BCVA) of 20/40 to 20/320 by Early Treatment Diabetic Retinopathy Study (ETDRS) Protocol Exclusion Criteria: * Neovascularization secondary to any other condition than AMD in the study eye * Blood occupying greater than 50% of the AMD lesion, or blood \> 1.0 sq. mm underlying the fovea * PED without associated subretinal fluid and/or cystic retinal changes * Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye * Confounding ocular conditions in the study eye which will affect interpretation of OCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane, retinal vascular occlusive disease) * Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye or any condition preventing VA improvement * Uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma medication in the study eye